4.5 Article

Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit

期刊

RESPIRATORY MEDICINE
卷 109, 期 6, 页码 743-750

出版社

W B SAUNDERS CO LTD
DOI: 10.1016/j.rmed.2015.04.007

关键词

Pneumonia; Cohort; Epidemiology; Infection; Outcomes; Sepsis

资金

  1. Bayer HealthCare
  2. Pfizer
  3. Merck Sharp Dohne
  4. AstraZeneca
  5. Basilea
  6. GlaxoSmithKline
  7. Wellcome Trust
  8. Medical Research Council
  9. Chief Scientist Office
  10. Tenovus Scotland
  11. European Respiratory Society

向作者/读者索取更多资源

Introduction: Severe community-acquired pneumonia (CAP) portends a serious prognosis. The temporal trend in outcome of severe CAP is not well established. We evaluated the temporal trends in the outcomes of severe CAP. Methods: This is a secondary analysis of 800 patients with severe CAP enrolled in the Community-Acquired Pneumonia Organization International Cohort. Severe CAP was defined as CAP requiring admission to the intensive care unit. Only patients admitted to the ICU upon hospital admission were included in this study. We assessed the trend in outcomes of these patients during three time periods: Period I (June 2001 to April 2004), Period II (May 2004 to January 31 2008), and Period III (February 2008 to February 2013). Results: After adjustment for other variables, mortality was higher for patients admitted during Period II compared with Period I (RR: 1.46; 95% CI: 1.002 to 2.14; P value = 0.049), and for Period III compared with Period I (RR: 1.70; 95% CI: 1.15 to 2.50; P value = 0.008). No significant difference in length of stay or time to clinical stability was found among the three periods. Conclusion: The mortality of patients with severe CAP increased over time in our study population. This finding has important health policy implications if confirmed by other studies. (C) 2015 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据